Precirix is a biotechnology company focused on developing precision radiopharmaceuticals aimed at improving cancer treatment outcomes. The company utilizes camelid single-domain antibodies (sdAb) that are labeled with radiometals to create targeted therapies. Their lead program is centered on targeting Fibroblast Activation Protein (FAP), which is a pan-tumor target, and is progressing towards clinical application. This innovative approach positions Precirix to potentially introduce the first alpha-emitting targeted radiotherapy for FAP, marking a significant advancement in cancer treatment.

In addition to their lead program, Precirix is actively researching various isotopes, linker technologies, and combination therapies to broaden their therapeutic platform. This ongoing research aims to enhance the efficacy and applicability of their radiopharmaceuticals, addressing unmet medical needs in oncology. The company is committed to improving the lives of cancer patients through the development of novel treatments that leverage their unique technological capabilities.

Belgium

PRECIRIX® is a clinical-stage biotechnology company dedicated to improving the lives of cancer patients by developing novel targeted radiopharmaceuticals using camelid single domain antibody fragments.

The company is advancing its lead product CAM-H2 through a Phase I/II clinical trial targeting HER2-positive tumors, while further progressing and broadening its oncology pipeline.

PRECIRIX' technology platform allows for a theranostic approach, using the same molecule for patient selection (imaging) and therapy.

Precirix

Company Details